Top 10 Best-Selling Drugs Of Q1 2023: Keytruda Topples Humira
COVID-19 Products And Humira Decline As Keytruda Continues Ascent
A review of the top-selling drugs of the first quarter of 2023 demonstrate the declining turnover from products to treat or prevent COVID-19, as well as a precipitative drop by Humira. Merck & Co’s PD-1 inhibitor Keytruda grew strongly, and Novo Nordisk’s injectable diabetes drug Ozempic burst into the top 10 ranks.
